Romania Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

Romania Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

Romania's cardiovascular disease therapeutics market is expected to witness growth from $472 Mn in 2022 to $839 Mn in 2030 with a CAGR of 7.47% for the forecasted year 2022-30. due to the rising prevalence of cardiovascular diseases and government-initiated awareness programs such as "Alianta Romania Respira" and "PROFI iubeste sanatatea". The Romania cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and end user. Fiterman Pharma, Polisano Pharmaceuticals, and Pfizer are the major players in the Romania cardiovascular disease therapeutics market.

ID: IN10ROPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Parul Choudhary

Buy Now

Romania Cardiovascular Disease Therapeutics Market Executive Analysis

Romania's cardiovascular disease therapeutics market is expected to witness growth from $472 Mn in 2022 to $839 Mn in 2030 with a CAGR of 7.47% for the forecasted year 2022-30. Compared to other European nations, Romania spends a comparatively small amount on healthcare. Romania spent about 6% of its GDP on healthcare in 2022, which is considerably less than the 10% average for the European Union. There are issues with the healthcare infrastructure, medication access, and healthcare staff as a result of this low amount of spending. In general, Romania's health results are subpar when compared to those of other European nations. The incidence of communicable illnesses like HIV/AIDS and tuberculosis is significant in the nation, as is the prevalence of non-communicable diseases like cancer and cardiovascular conditions. In comparison to other European nations, the nation also has a high infant mortality rate and a poor life expectancy.

Romania has the highest rates of cardiovascular mortality in Europe, and Romanian general practitioners' (GP) workloads are heavily influenced by cardiovascular pathology. Every fourth adult patient seen by a GP is a cardiovascular patient, according to the findings of the Sentinel Network Project, in which 100 Romanian GPs collected medical data over three years using the ICPC classification. The most common causes of encounters, diagnoses, prescriptions, and recommendations are cardiovascular diseases.

Recent progress in the research of the molecules that control cardiac function demonstrates that gene molecules are essential for treating heart failure. Additionally, a paracrine mechanism theory, one of the positive outcomes of cell therapy, encourages us to look for novel target molecules for pharmacological strategy. Delivering genetic material to cells in order to achieve desired therapeutic results is known as gene transfer therapy. Gene therapy for the cardiovascular system has advanced significantly recently, and clinical research on a number of novel therapeutic target genes has started. Some desired positive outcomes have already been attained. A variety of clinical trials for acute myocardial infarction and chronic Heart Failure (HF) have been performed, and among all the bioactive agents, cytokines like granulocyte colony-stimulating factor and erythropoietin have been thoroughly investigated. However, more study into molecular processes, safety, and high efficacy is needed in preclinical and clinical settings.

Romania Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The key source of death and morbidity in Romania is cardiovascular disease (CVD). The World Health Organization (WHO) reports that in 2016, 56% of all fatalities in Romania were caused by CVDs. Therapeutics for cardiovascular diseases are now in higher demand as a result of this. The government programs "Alianta Romania Respira" and "PROFI iubeste sanatatea" have facilitated increased awareness of the risk factors for CVDs among the Romanian people. As a result, there is an intensifying requirement for cardiovascular disease prevention approaches and remedies leading to the expansion of the Romania cardiovascular disease therapeutics market.

Market Restraints

Compared to other European nations, Romania spends a small amount on healthcare. The government's capacity to fund healthcare services and facilities, including therapeutics for cardiovascular diseases, has been hampered as a result. Despite initiatives to increase access to healthcare, Romania still has large regional disparities in healthcare availability. This may make it more difficult for patients to obtain necessary therapeutics for their cardiovascular disease hence limiting the expansion of the Romania cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

Farmex (ROU)
Rontis Romania Pharma (ROU)
Biotehnos (ROU)
Fiterman Pharma (ROU)
Polisano Pharmaceuticals (ROU)
Pfizer
AstraZeneca
Merck
Sanofi
Novartis
Daiichi Sankyo

Healthcare Policies and Regulatory Landscape

The National Health Insurance Fund (CNAS) and the Ministry of Health supervise the policies for cardiovascular health care and reimbursement in Romania. The national health insurance program in Romania offers free medical treatment to all of its residents, making it a nation with a universal healthcare system. This covers all essential medications and approaches for treating cardiovascular disease. The CNAS determines the compensation amounts for procedures, medications, and treatments for cardiovascular diseases. Generic medications and treatments generally have lower reimbursement rates than branded medications and pioneering therapies. In Romania, access to medications for cardiovascular diseases can be constrained, especially for novel and expensive treatments. The "Pharmaceuticals for Rare Diseases" program, which offers free medications to people with rare cardiovascular diseases, is one of several government initiatives to increase access to medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.